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Purpose
The aim of this study was to determine the genetic
components contributing to the different systemic
sclerosis (SSc) clinical sub-phenotypes of limited (lcSSc)
and diffuse (dcSSc) cutaneous involvement, and with
the most common SSc-specific autoantibodies, anti-
centromere (ACA) and anti-topoisomerase I (ATA)
through a genome-wide association study (GWAS) and a
large replication study stratified for these disease features.
Methods
In the discovery phase 2,296 SSc patients and 5,171
healthy controls were analyzed for genetic associations in
lcSSc, dcSSc, ACA positive and ATA positive subgroups.
The non-HLA SNPs associated with each subphenotype
with a genomic control corrected P value lower than
1x10
-5, not previously associated with SSc, were selected
for replication in 9 independent cohorts from the US and
Europe comprising an additional 3,175 SSc patients and
4,971 controls. In addition, meta-analyses including all
patients and healthy controls were conducted for each
subphenotype.
Results
Three out of the 18 non-HLA SNPs selected for replica-
tion showed evidence of association. Meta-analysis includ-
ing GWAS and replication cohorts showed a strong
association of IRF8 rs11642873 polymorphism (P =
2.32x10
-12, OR = 0.75) and a suggestive but consistent
association among populations of GRB10 rs12540874
polymorphism (P = 1.27x10
-6, OR = 1.15) with the lcSSc
subtype of the disease. Furthermore, significant association
of SOX5 rs11047102 polymorphism (P = 1.39x10
-7,O R=
1.36) with the ACA positive patients was detected. In the
HLA region, specific patterns of SNPs associated with the
ACA and ATA subgroups were observed, reflected by
highly associated haplotype in the HLA-DQB1 locus with
ACA (P = 1.79x10
-61), and in the HLA-DPA1/B1 loci alle-
lic combination with ATA (P = 4.57x10
-76).
Conclusions
We have identified three new genes (IRF8, GRB10, and
SOX5) associated with clinical manifestations of SSc,
emphasizing the differential genetic component of each
subphenotype of this disease. Within the HLA region,
we have observed that HLA-DQB1 and HLA-DPA1/B1
associations with SSc are likely confined to specific
auto-antibody positive patients.
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